We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
-9.85%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$110M
AUM Growth
-$25.2M
Cap. Flow
+$1.67M
Cap. Flow %
1.52%
Top 10 Hldgs %
66.13%
Holding
26
New
5
Increased
2
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$12.7M
2
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$5.22M
3
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$5.15M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$3.92M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$3.57M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$10.7M
2
ARVN icon
Arvinas
ARVN
+$10.1M
3
NTLA icon
Intellia Therapeutics
NTLA
+$4.36M
4
SGHT icon
Sight Sciences
SGHT
+$3.64M
5
COGT icon
Cogent Biosciences
COGT
+$3.09M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$14.9M 13.59%
+39,370
New +$12.7M
MDVL
2
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$9.02M 8.22%
117,898
+59,482
+102% +$5.22M
COGT icon
3
Cogent Biosciences
COGT
$6.68B
$7.73M 7.05%
857,352
-452,078
-35% -$3.09M
LNTH icon
4
Lantheus
LNTH
$7B
$7.59M 6.92%
115,000
-170,000
-60% -$10.7M
GH icon
5
Guardant Health
GH
$20.7B
$6.45M 5.88%
160,000
– –
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.25M 5.7%
650,000
– –
GOSS icon
7
Gossamer Bio
GOSS
$83.2M
$5.86M 5.34%
700,000
+250,000
+56% +$1.94M
VRDN icon
8
Viridian Therapeutics
VRDN
$1.99B
$5.74M 5.23%
496,012
– –
FATE icon
9
Fate Therapeutics
FATE
$324M
$4.5M 4.1%
181,500
– –
CERE
10
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.5M 4.1%
170,000
– –
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.37M 3.99%
+250,000
New +$3.92M
NUVB icon
12
Nuvation Bio
NUVB
$2.02B
$3.68M 3.36%
1,137,152
– –
ISO
13
DELISTED
IsoPlexis Corporation Common Stock
ISO
$3.56M 3.25%
1,650,118
– –
SLGC
14
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.32M 3.03%
735,000
– –
SYRS
15
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.24M 2.95%
336,490
– –
DICE
16
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.22M 2.93%
+207,290
New +$3.57M
RLMD icon
17
Relmada Therapeutics
RLMD
$550M
$3.04M 2.77%
+160,000
New +$3.49M
RPID icon
18
Rapid Micro Biosystems
RPID
$103M
$3.01M 2.74%
699,664
– –
NAUT icon
19
Nautilus Biotechnolgy
NAUT
$221M
$2.91M 2.65%
1,080,566
– –
SNCE
20
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.83M 2.58%
+70,508
New +$5.15M
STOK icon
21
Stoke Therapeutics
STOK
$1.81B
$2.31M 2.11%
175,000
– –
JNCE
22
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.67M 1.52%
550,000
– –
ARVN icon
23
Arvinas
ARVN
$517M
– –
-150,000
Closed -$10.1M
NTLA icon
24
Intellia Therapeutics
NTLA
$1.59B
– –
-60,000
Closed -$4.36M
SGHT icon
25
Sight Sciences
SGHT
$274M
– –
-314,804
Closed -$3.64M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q2 2022 Portfolio in Review

As of Q2 2022, Ally Bridge Group held 26 positions worth $110M, down 19% from $135M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Ally Bridge Group's Q2 2022 filing shows 5 new, 2 increased, 2 reduced and 4 closed positions. Its largest new stake was argenx: 39,370 shares worth $14.9M. The largest sale was Lantheus, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Ally Bridge Group's largest Q2 2022 buy was argenx: 39,370 shares worth $14.9M.
  • Ally Bridge Group added most to MedAvail Holdings, Inc. Common Stock in Q2 2022, an estimated $5.22M increase.
  • Ally Bridge Group's biggest Q2 2022 reduction was Lantheus, cutting an estimated $10.7M.
  • Ally Bridge Group fully exited Arvinas in Q2 2022, selling an estimated $10.1M.
  • Ally Bridge Group's ten largest holdings make up 66% of its $110M portfolio in Q2 2022.
  • Ally Bridge Group opened 5 new positions and closed 4 in Q2 2022.
  • Ally Bridge Group's portfolio value fell 19% quarter-over-quarter to $110M.

Based on Ally Bridge Group's 13F filing for Q2 2022, filed 15 Aug 2022.